Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults

By M. Mulligan, Kirsten E. Lyke, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, K. Neuzil, V. Raabe, R. Bailey, K. Swanson and 15 more. Nature, 2020

1,348 citations recorded by the source corpus.

Subfields: Animal Science and Zoology, Infectious Diseases, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/afe4cc71f4814fce21031c3f15998576c7175b1a

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. de Figueiredo
2. Sahil Loomba
3. H. Larson
4. S. Piatek
5. K. de Graaf

Citations in the corpus

• Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein (2021, neutral): “Furthermore, candidate vaccines that include only RBD antigens lack the ability to induce NTDreactive neutralizing antibodies (Laczko et al., 2020; Mulligan et al., 2020; Smith et al., 2020; Yu et al., 2020).”
• Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA (2021, background): “The image metrics considered are, in order, whether (1) the respondents perceived the image to have made them less inclined to vaccinate, (2) they agreed with the image, (3) they found the image trustworthy, (4) they were likely to fact check the information shown in the image, and (5) they were lik”